<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36121612</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1950</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>13</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Drugs</Title><ISOAbbreviation>Drugs</ISOAbbreviation></Journal><ArticleTitle>Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents.</ArticleTitle><Pagination><StartPage>1367</StartPage><EndPage>1388</EndPage><MedlinePgn>1367-1388</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40265-022-01769-1</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder involving loss of upper and lower motor neurons, with most cases ending in death within 3-5 years of onset. Several molecular and cellular pathways have been identified to cause ALS; however, treatments to stop or reverse disease progression are yet to be found. Riluzole, a neuroprotective agent offering only a modest survival benefit, has long been the sole disease-modifying therapy for ALS. Edaravone, which demonstrated statistically significant slowing of ALS disease progression, is gaining approval in an increasing number of countries since its first approval in 2015. Sodium phenylbutyrate and taurursodiol (PB-TURSO) was conditionally approved in Canada in 2022, having shown significant slowing of disease progression and prolonged survival. Most clinical trials have focused on testing small molecules affecting common cellular pathways in ALS: targeting glutamatergic, apoptotic, inflammatory, and oxidative stress mechanisms among others. More recently, clinical trials utilizing stem cell transplantation and other biologics have emerged. This rich and ever-growing pipeline of investigational products, along with innovative clinical trial designs, collaborative trial networks, and an engaged ALS community', provide renewed hope to finding a cure for ALS. This article reviews existing ALS therapies and the current clinical drug development pipeline.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Johnson</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0002-9058-4331</Identifier><AffiliationInfo><Affiliation>Neurological Clinical Research Institute (NCRI), Healey &amp; AMG Center for ALS, Massachusetts General Hospital, 165 Cambridge St, Suite 600, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Fang</LastName><ForeName>Ton</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-2119-9015</Identifier><AffiliationInfo><Affiliation>University of Massachusetts Medical School, Worcester, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>De Marchi</LastName><ForeName>Fabiola</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0197-1880</Identifier><AffiliationInfo><Affiliation>Department of Neurology, ALS Centre, Maggiore della Carit&#xe0; Hospital, Novara, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Translational Medicine, University of Piemonte Orientale, 28100, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neel</LastName><ForeName>Dylan</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-6964-9842</Identifier><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Weehaeghe</LastName><ForeName>Donatienne</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-6646-106X</Identifier><AffiliationInfo><Affiliation>Nuclear Medicine Subdivision, Department of Imaging and Pathology, University Hospital Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0003-0898-6081</Identifier><AffiliationInfo><Affiliation>Neurological Clinical Research Institute (NCRI), Healey &amp; AMG Center for ALS, Massachusetts General Hospital, 165 Cambridge St, Suite 600, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paganoni</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0505-1168</Identifier><AffiliationInfo><Affiliation>Neurological Clinical Research Institute (NCRI), Healey &amp; AMG Center for ALS, Massachusetts General Hospital, 165 Cambridge St, Suite 600, Boston, MA, 02114, USA. spaganoni@mgh.harvard.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Boston, MA, USA. spaganoni@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 GM007753</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM144273</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drugs</MedlineTA><NlmUniqueID>7600076</NlmUniqueID><ISSNLinking>0012-6667</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001688">Biological Products</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001688" MajorTopicYN="Y">Biological Products</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="Y">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="N">Riluzole</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>19</Day><Hour>11</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36121612</ArticleId><ArticleId IdType="doi">10.1007/s40265-022-01769-1</ArticleId><ArticleId IdType="pii">10.1007/s40265-022-01769-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shefner JM, Al-Chalabi A, Baker MR, et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131(8):1975&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">32387049</ArticleId><ArticleId IdType="doi">10.1016/j.clinph.2020.04.005</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119(3):497&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">18164242</ArticleId><ArticleId IdType="doi">10.1016/j.clinph.2007.09.143</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial &#x201c;Clinical limits of amyotrophic lateral sclerosis&#x201d; workshop contributors. J Neurol Sci. 1994;124:96&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">7807156</ArticleId><ArticleId IdType="doi">10.1016/0022-510X(94)90191-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Shatunov A, Al-Chalabi A. The genetic architecture of ALS. Neurobiol Dis. 2021;147: 105156.</Citation><ArticleIdList><ArticleId IdType="pubmed">33130222</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2020.105156</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters OM, Ghasemi M, Brown RH Jr. Emerging mechanisms of molecular pathology in ALS. J Clin Invest. 2015;125(5):1767&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">25932674</ArticleId><ArticleId IdType="pmc">4463186</ArticleId><ArticleId IdType="doi">10.1172/JCI71601</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH Jr, Cleveland DW, Decoding ALS. from genes to mechanism. Nature. 2016;539:197.</Citation><ArticleIdList><ArticleId IdType="pubmed">27830784</ArticleId><ArticleId IdType="pmc">5585017</ArticleId><ArticleId IdType="doi">10.1038/nature20413</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, et al. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci. 2019;13:1310.</Citation><ArticleIdList><ArticleId IdType="pubmed">31866818</ArticleId><ArticleId IdType="pmc">6909825</ArticleId><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso A, Logroscino G, Hern&#xe1;n MA. Smoking and the risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2010;81(11):1249&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">20639382</ArticleId><ArticleId IdType="doi">10.1136/jnnp.2009.180232</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, Horton DK, Mitsumoto H. Potential environmental factors in amyotrophic lateral sclerosis. Neurol Clin. 2015;33(4):877&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">26515627</ArticleId><ArticleId IdType="pmc">4646848</ArticleId><ArticleId IdType="doi">10.1016/j.ncl.2015.07.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Rothstein JD, Kiernan MC. Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends Neurosci. 2014;37(8):433&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">24927875</ArticleId><ArticleId IdType="doi">10.1016/j.tins.2014.05.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Hardiman O, Al-Chalabi A, et al. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol. 2022;21(5):465&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">35334234</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(21)00414-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Calvo A, Chio A, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014;13(11):1108&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">25300936</ArticleId><ArticleId IdType="pmc">4197338</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(14)70219-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadon-Nachum M, Melamed E, Offen D. The &#x201c;dying-back&#x201d; phenomenon of motor neurons in ALS. J Mol Neurosci. 2011;43(3):470&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21057983</ArticleId><ArticleId IdType="doi">10.1007/s12031-010-9467-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, Culver DG, Tennant P, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. 2004;185(2):232&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">14736504</ArticleId><ArticleId IdType="doi">10.1016/j.expneurol.2003.10.004</ArticleId></ArticleIdList></Reference><Reference><Citation>IQVIA. Understanding neuromuscular disease care: current state and future prospects. Current State and Future Prospects [online] 2018 2018 October 30 [cited 2022 August 5]. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports/understanding-neuromuscular-disease-care .</Citation></Reference><Reference><Citation>Kiernan MC, Vucic S, Talbot K, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol. 2021;17(2):104&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">33340024</ArticleId><ArticleId IdType="doi">10.1038/s41582-020-00434-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Berry JD, Quintana M, et al. Adaptive platform trials to transform amyotrophic lateral sclerosis therapy development. Ann Neurol. 2022;91(2):165&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">34935174</ArticleId><ArticleId IdType="doi">10.1002/ana.26285</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330(9):585&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347(9013):1425&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">8676624</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(96)91680-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Bosch L, Van Damme P, Bogaert E, et al. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochimica et Biophysica Acta (BBA) Mol Basis Dis. 2006;1762(11):1068&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2006.05.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoing MC, Burke D, Pamphlett R, et al. Riluzole therapy for motor neurone disease: an early Australian experience (1996&#x2013;2002). J Clin Neurosci. 2006;13(1):78&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">16410201</ArticleId><ArticleId IdType="doi">10.1016/j.jocn.2004.04.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Riviere M, Meininger V, Zeisser P, et al. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol. 1998;55(4):526&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9561981</ArticleId><ArticleId IdType="doi">10.1001/archneur.55.4.526</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoccolella S, Beghi E, Palagano G, et al. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2008;79(1):33&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17550991</ArticleId><ArticleId IdType="doi">10.1136/jnnp.2007.118018</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Alexander M, Corr B, et al. An outcome study of riluzole in amyotrophic lateral sclerosis&#x2014;a population-based study in Ireland, 1996&#x2013;2000. J Neurol. 2003;250(4):473&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12700914</ArticleId><ArticleId IdType="doi">10.1007/s00415-003-1026-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, Menon P, Ng K, et al. Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS. Amyotroph Lateral Scler Frontotemp Degener. 2016;17(7&#x2013;8):580&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1188961</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Jackson CE, Heiman-Patterson TD, et al. Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemp Degener. 2020;21(7&#x2013;8):509&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1771734</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Meurgey JH, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17(5):416&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">29525492</ArticleId><ArticleId IdType="pmc">5899963</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(18)30054-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Seibold H, Zeileis A, Hothorn T. Individual treatment effect prediction for amyotrophic lateral sclerosis patients. Stat Methods Med Res. 2018;27(10):3104&#x2013;125.</Citation></Reference><Reference><Citation>Hodgkinson VL, Lounsberry J, Mirian A, et al. Provincial differences in the diagnosis and care of amyotrophic lateral sclerosis. Can J Neurol Sci. 2018;45(6):652&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30430962</ArticleId><ArticleId IdType="doi">10.1017/cjn.2018.311</ArticleId></ArticleIdList></Reference><Reference><Citation>Qureshi I, Lovegren M, Wirtz V, et al. A pharmacokinetic bioequivalence study comparing sublingual riluzole (BHV-0223) and oral tablet formulation of riluzole in healthy volunteers. Clin Pharmacol Drug Dev. 2020;9(4):476&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">31610101</ArticleId><ArticleId IdType="doi">10.1002/cpdd.747</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Bettica P, Cazzaniga S. Riluzole oral suspension: bioavailability following percutaneous gastrostomy tube-modeled administration versus direct oral administration. Clin Ther. 2019;41(12):2490&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">31635890</ArticleId><ArticleId IdType="doi">10.1016/j.clinthera.2019.09.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyer AM, Smith A. Riluzole 5 mg/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis. Drug Des Dev Ther. 2017;11:59&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S123776</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe K, Tanaka M, Yuki S, et al. How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? J Clin Biochem Nutr. 2018;62(1):20&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">29371752</ArticleId><ArticleId IdType="doi">10.3164/jcbn.17-62</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz MP. Edaravone (Radicava): a novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis. P T. 2018;43(1):25&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29290672</ArticleId><ArticleId IdType="pmc">5737249</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler. 2006;7(4):241&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">17127563</ArticleId><ArticleId IdType="doi">10.1080/17482960600881870</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki M, Warita H, Mizuno H, et al. Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger. Brain Res. 2011;1382:321&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">21276427</ArticleId><ArticleId IdType="doi">10.1016/j.brainres.2011.01.058</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H, Wate R, Zhang J, et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol. 2008;213(2):448&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">18718468</ArticleId><ArticleId IdType="doi">10.1016/j.expneurol.2008.07.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Iwasaki Y. Edaravone, a free radical scavenger, delayed symptomatic and pathological progression of motor neuron disease in the wobbler mouse. PLoS ONE. 2015;10(10): e0140316.</Citation><ArticleIdList><ArticleId IdType="pubmed">26469273</ArticleId><ArticleId IdType="pmc">4607459</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0140316</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Itoyama Y, Sobue G, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemp Degener. 2014;15(7&#x2013;8):610&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.959024</ArticleId></ArticleIdList></Reference><Reference><Citation>Edaravone Als 16 Study G. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemp Degener. 2017;18(sup 1):11&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1363780</ArticleId></ArticleIdList></Reference><Reference><Citation>Group W. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Witzel S, Maier A, Steinbach R, et al. Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2022;79(2):121&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">35006266</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2021.4893</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, Moglia C, Lizio A, et al. The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. J Neurol. 2020;267(11):3258&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">32556567</ArticleId><ArticleId IdType="doi">10.1007/s00415-020-09993-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing G and Edaravone ALSSG. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group On Behalf Of The Edaravone Als 19 Study G. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemp Degener. 2017;18(sup 1):55&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1364269</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H, Nishimura Y, Shiide Y, et al. Bioequivalence study of oral suspension and intravenous formulation of edaravone in healthy adult subjects. Clin Pharmacol Drug Dev. 2021;10(10):1188&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">33955162</ArticleId><ArticleId IdType="pmc">8518908</ArticleId><ArticleId IdType="doi">10.1002/cpdd.952</ArticleId></ArticleIdList></Reference><Reference><Citation>TRICALS. Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of FNP122 for people with amyotrophic lateral sclerosis (ALS). 2021 [cited 2022 August 5]. Available from: https://www.tricals.org/en/trials/adore-als-trial/ .</Citation></Reference><Reference><Citation>Al-Chalabi A, Andersen PM, Chandran S, et al. July 2017 ENCALS statement on edaravone. Amyotroph Lateral Scler Frontotemp Degener. 2017;18(7&#x2013;8):471&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1369125</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu M, Tortorice K, Zacher J, et al. Assessment of use and safety of edaravone for amyotrophic lateral sclerosis in the veterans affairs health care system. JAMA Netw Open. 2020;3(10):e2014645&#x2013;e2014645.</Citation><ArticleIdList><ArticleId IdType="pubmed">33017028</ArticleId><ArticleId IdType="pmc">7536587</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.14645</ArticleId></ArticleIdList></Reference><Reference><Citation>America MTP. More than 4,000 U.S. patients with ALS treated with RADICAVA<sup>&#xae;</sup> (edaravone) in two years since availability. Mitsubishi Tanabe Pharma America Reports, 2019, Mitsubishi Tanabe Pharma America. https://www.mt-pharma-america.com/ .</Citation></Reference><Reference><Citation>Mehta P, Kaye W, Bryan L, et al. Prevalence of amyotrophic lateral sclerosis&#x2014;United States, 2012&#x2013;2013. MMWR Surveill Summ. 2016;65(8):1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">27490513</ArticleId><ArticleId IdType="doi">10.15585/mmwr.ss6508a1</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Brooks BR, Swain-Eng RJ, et al. Quality improvement in neurology: amyotrophic lateral sclerosis quality measures: report of the quality measurement and reporting subcommittee of the American Academy of Neurology. Neurology. 2013;81(24):2136&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">24271651</ArticleId><ArticleId IdType="pmc">3863352</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000437305.37850.f9</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">32877582</ArticleId><ArticleId IdType="pmc">9134321</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId></ArticleIdList></Reference><Reference><Citation>Elia AE, Lalli S, Monsurr&#xf2; MR, et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2016;23(1):45&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">25664595</ArticleId><ArticleId IdType="doi">10.1111/ene.12664</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Andres PL, Macdonald SA, et al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler. 2009;10(2):99&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">18688762</ArticleId><ArticleId IdType="doi">10.1080/17482960802320487</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogarth P, Lovrecic L, Krainc D. Sodium phenylbutyrate in Huntington&#x2019;s disease: a dose-finding study. Mov Disord. 2007;22(13):1962&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">17702032</ArticleId><ArticleId IdType="doi">10.1002/mds.21632</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Hendrix S, Dickson SP, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63(1):31&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">33063909</ArticleId><ArticleId IdType="doi">10.1002/mus.27091</ArticleId></ArticleIdList></Reference><Reference><Citation>Gohsler B. Amylyx pharmaceuticals announces FDA plan to reconvene Advisory Committee to review AMX0035 NDA for the treatment of ALS on September 7, 2022. amylyx.com.</Citation></Reference><Reference><Citation>Gohsler B. Amylyx pharmaceuticals announces EMA validation of Marketing Authorisation Application (MAA) for AMX0035 for the treatment of ALS; 2022. Amylyx.com.</Citation></Reference><Reference><Citation>Pharmaceuticals A. Product monograph including patient medication information. Health Canada; 2022.</Citation></Reference><Reference><Citation>Canada H. Notice of compliance with conditions&#x2014;NOC/c (therapeutic products). Drug products [Web Page] 2007 2007 May 17 [cited 2022 August 5]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/fact-sheets/notice-compliance-conditions-therapeutics-products.html .</Citation></Reference><Reference><Citation>Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology. 2004;63(8):1364&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">15505150</ArticleId><ArticleId IdType="doi">10.1212/01.WNL.0000142042.50528.2F</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Jozsa F, Al-Chalabi A. Nonmotor symptoms in amyotrophic lateral sclerosis: a systematic review. Int Rev Neurobiol. 2017;134:1409&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">28805578</ArticleId><ArticleId IdType="doi">10.1016/bs.irn.2017.04.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvizi J, Anderson SW, Martin CO, et al. Pathological laughter and crying: a link to the cerebellum. Brain. 2001;124(Pt 9):1708&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">11522574</ArticleId><ArticleId IdType="doi">10.1093/brain/124.9.1708</ArticleId></ArticleIdList></Reference><Reference><Citation>Green JR, Allison KM, Cordella C, et al. Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: a quantitative speech analysis. Br J Clin Pharmacol. 2018;84(12):2849&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">30152872</ArticleId><ArticleId IdType="pmc">6256051</ArticleId><ArticleId IdType="doi">10.1111/bcp.13745</ArticleId></ArticleIdList></Reference><Reference><Citation>Pioro EP. Review of dextromethorphan 20 mg/quinidine 10 mg (NUEDEXTA((R))) for pseudobulbar affect. Neurol Ther. 2014;3(1):15&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">26000221</ArticleId><ArticleId IdType="pmc">4381919</ArticleId><ArticleId IdType="doi">10.1007/s40120-014-0018-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Pioro E, Myers K, et al. Enhanced bulbar function in amyotrophic lateral sclerosis: the Nuedexta treatment trial. Neurotherapeutics. 2017;14(3):762&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">28070747</ArticleId><ArticleId IdType="pmc">5509619</ArticleId><ArticleId IdType="doi">10.1007/s13311-016-0508-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68(5):693&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">20839238</ArticleId><ArticleId IdType="doi">10.1002/ana.22093</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate). In: FDA, editor. FDA; 2010. p. 19. accessdata.fda.gov.</Citation></Reference><Reference><Citation>Oki R, Izumi Y, Fujita K, et al. Efficacy and safety of ultrahigh-dose methylcobalamin in early-stage amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol. 2022;79(6):575&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">35532908</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2022.0901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaji R, Imai T, Iwasaki Y, et al. Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study. J Neurol Neurosurg Psychiatry. 2019;90(4):451&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">30636701</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2018-319294</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Karam C, Joyce N, et al. Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis. NeuroRehabilitation. 2015;37(1):53&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">26409693</ArticleId><ArticleId IdType="pmc">5223769</ArticleId><ArticleId IdType="doi">10.3233/NRE-151240</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1227&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">19822873</ArticleId><ArticleId IdType="pmc">2764728</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3181bc01a4</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1218&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">19822872</ArticleId><ArticleId IdType="pmc">2764727</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e3181bc0141</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, Moore D, Mozaffar T, et al. Mexiletine for muscle cramps in amyotrophic lateral sclerosis: a randomized, double-blind crossover trial. Muscle Nerve. 2018.</Citation></Reference><Reference><Citation>Shibuya K, Misawa S, Kimura H, et al. A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: efficacy and safety of sodium channel blocker phase II trial. Amyotroph Lateral Scler Frontotemp Degener. 2015;16(5&#x2013;6):353&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1038277</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss MD, Macklin EA, Simmons Z, et al. A randomized trial of mexiletine in ALS: safety and effects on muscle cramps and progression. Neurology. 2016;86(16):1474&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">26911633</ArticleId><ArticleId IdType="pmc">4836879</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000002507</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Kiernan MC, Menon P, et al. Study protocol of RESCUE-ALS: a Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression. BMJ Open. 2021;11(1): e041479.</Citation><ArticleIdList><ArticleId IdType="pubmed">33431491</ArticleId><ArticleId IdType="pmc">7802642</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2020-041479</ArticleId></ArticleIdList></Reference><Reference><Citation>Ionescu A, Gradus T, Altman T, et al. Targeting the sigma-1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1(G93A) model. Cell Death Dis. 2019;10(3):210.</Citation><ArticleIdList><ArticleId IdType="pubmed">30824685</ArticleId><ArticleId IdType="pmc">6397200</ArticleId><ArticleId IdType="doi">10.1038/s41419-019-1451-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Guo Y, Wang X, et al. Trehalose decreases mutant SOD1 expression and alleviates motor deficiency in early but not end-stage amyotrophic lateral sclerosis in a SOD1-G93A mouse model. Neuroscience. 2015;298:12&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">25841320</ArticleId><ArticleId IdType="doi">10.1016/j.neuroscience.2015.03.061</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong C, Dakin RS, Williamson J, et al. Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease. BMJ Open. 2022;12(7): e064173.</Citation><ArticleIdList><ArticleId IdType="pubmed">35798516</ArticleId><ArticleId IdType="pmc">9263927</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2022-064173</ArticleId></ArticleIdList></Reference><Reference><Citation>Decressac M, Mattsson B, Weikop P, et al. TFEB-mediated autophagy rescues midbrain dopamine neurons from &#x3b1;-synuclein toxicity. Proc Natl Acad Sci USA. 2013;110(19):E1817&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">23610405</ArticleId><ArticleId IdType="pmc">3651458</ArticleId><ArticleId IdType="doi">10.1073/pnas.1305623110</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu S, Hightower BG, Chan J, et al. Ibudilast (MN-166) in amyotrophic lateral sclerosis&#x2014;an open label, safety and pharmacodynamic trial. Neuroimage Clin. 2021;30: 102672.</Citation><ArticleIdList><ArticleId IdType="pubmed">34016561</ArticleId><ArticleId IdType="pmc">8102622</ArticleId><ArticleId IdType="doi">10.1016/j.nicl.2021.102672</ArticleId></ArticleIdList></Reference><Reference><Citation>Commission E. Public summary of opinion on orphan designation&#x2014;Masitinib mesilate for treatment of amyotrophic lateral sclerosis. In: E.M. Agency, editor. Committee for Orphan Medicinal Products; 2016. ema.europea.eu.</Citation></Reference><Reference><Citation>Mora JS, Bradley WG, Chaverri D, et al. Long-term survival analysis of masitinib in amyotrophic lateral sclerosis. Ther Adv Neurol Disord. 2021;14:17562864211030364.</Citation><ArticleIdList><ArticleId IdType="pubmed">34457038</ArticleId><ArticleId IdType="pmc">8388186</ArticleId><ArticleId IdType="doi">10.1177/17562864211030365</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, Genge A, Chio A, et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemp Degener. 2020;21(1&#x2013;2):5&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632346</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Andrews JA, Genge A, et al. A phase 2, double-blind, randomized, dose-ranging trial of reldesemtiv in patients with ALS. Amyotroph Lateral Scler Frontotemp Degener. 2021;22(3&#x2013;4):287&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1822410</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunn JS, Sakowski SA, Feldman EL. Concise review: stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future. Stem Cells. 2014;32(5):1099&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">24448926</ArticleId><ArticleId IdType="doi">10.1002/stem.1628</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman EL, Boulis NM, Hur J, et al. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol. 2014;75(3):363&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">24510776</ArticleId><ArticleId IdType="pmc">4005820</ArticleId><ArticleId IdType="doi">10.1002/ana.24113</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass JD, Hertzberg VS, Boulis NM, et al. Transplantation of spinal cord-derived neural stem cells for ALS: analysis of phase 1 and 2 trials. Neurology. 2016;87(4):392&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">27358335</ArticleId><ArticleId IdType="pmc">4977116</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000002889</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L, Gelati M, Profico DC, et al. Human neural stem cell transplantation in ALS: initial results from a phase I trial. J Transl Med. 2015;13:17.</Citation><ArticleIdList><ArticleId IdType="pubmed">25889343</ArticleId><ArticleId IdType="pmc">4359401</ArticleId><ArticleId IdType="doi">10.1186/s12967-014-0371-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L, Ferrari D, Andjus PR, et al. Advances in stem cell therapy for amyotrophic lateral sclerosis. Expert Opin Biol Ther. 2018;18(8):865&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">30025485</ArticleId><ArticleId IdType="doi">10.1080/14712598.2018.1503248</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L, Ferrero I, Luparello V, et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a phase I clinical trial. Exp Neurol. 2010;223(1):229&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">19682989</ArticleId><ArticleId IdType="doi">10.1016/j.expneurol.2009.08.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L, Mareschi K, Ferrero I, et al. Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long-term safety study. Cytotherapy. 2012;14(1):56&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">21954839</ArticleId><ArticleId IdType="doi">10.3109/14653249.2011.613929</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis CM, Suzuki M. Therapeutic applications of mesenchymal stem cells for amyotrophic lateral sclerosis. Stem Cell Res Ther. 2014;5(2):32.</Citation><ArticleIdList><ArticleId IdType="pubmed">25157751</ArticleId><ArticleId IdType="pmc">4035799</ArticleId><ArticleId IdType="doi">10.1186/scrt421</ArticleId></ArticleIdList></Reference><Reference><Citation>Staff NP, Madigan NN, Morris J, et al. Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS. Neurology. 2016;87(21):2230&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">27784774</ArticleId><ArticleId IdType="pmc">5123559</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000003359</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Lindborg SR, Goyal NA, et al. A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle Nerve. 2022;65(3):291&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">34890069</ArticleId><ArticleId IdType="pmc">9305113</ArticleId><ArticleId IdType="doi">10.1002/mus.27472</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzma-Kozakiewicz M, Marchel A, Kaminska A, et al. Intraspinal transplantation of the adipose tissue-derived regenerative cells in amyotrophic lateral sclerosis in accordance with the current experts&#x2019; recommendations: choosing optimal monitoring tools. Stem Cells Int. 2018;2018:4392017&#x2013;4392017.</Citation><ArticleIdList><ArticleId IdType="pubmed">30158984</ArticleId><ArticleId IdType="pmc">6109475</ArticleId><ArticleId IdType="doi">10.1155/2018/4392017</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, Beghi E, Blanquer M, et al. Intraspinal stem cell transplantation for amyotrophic lateral sclerosis: ready for efficacy clinical trials? Cytotherapy. 2016;18(12):1471&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">27720637</ArticleId><ArticleId IdType="doi">10.1016/j.jcyt.2016.08.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi C, Wood MJA. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol. 2018;14(1):9&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">29192260</ArticleId><ArticleId IdType="doi">10.1038/nrneurol.2017.148</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">27939059</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(16)31408-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">29972757</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1716793</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RA, Miller TM, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Investig. 2006;116(8):2290&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16878173</ArticleId><ArticleId IdType="pmc">1518790</ArticleId><ArticleId IdType="doi">10.1172/JCI25424</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1&#x2013;2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId></ArticleIdList></Reference><Reference><Citation>Korobeynikov VA, Lyashchenko AK, Blanco-Redondo B, et al. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat Med. 2022;28(1):104&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">35075293</ArticleId><ArticleId IdType="pmc">8799464</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01615-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Laffita-Mesa JM, Paucar M, Svenningsson P. Ataxin-2 gene: a powerful modulator of neurological disorders. Curr Opin Neurol. 2021;34(4):578&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">34010218</ArticleId><ArticleId IdType="pmc">8279897</ArticleId><ArticleId IdType="doi">10.1097/WCO.0000000000000959</ArticleId></ArticleIdList></Reference><Reference><Citation>Laffita-Mesa JM, Rodr&#xed;guez Pupo JM, Moreno Sera R, et al. De novo mutations in ataxin-2 gene and ALS risk. PLoS ONE. 2013;8(8): e70560.</Citation><ArticleIdList><ArticleId IdType="pubmed">23936447</ArticleId><ArticleId IdType="pmc">3735591</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0070560</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross OA, Rutherford NJ, Baker M, et al. Ataxin-2 repeat-length variation and neurodegeneration. Hum Mol Genet. 2011;20(16):3207&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">21610160</ArticleId><ArticleId IdType="pmc">3140823</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddr227</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, Huang B, Bieri G, et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544(7650):367&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">28405022</ArticleId><ArticleId IdType="pmc">5642042</ArticleId><ArticleId IdType="doi">10.1038/nature22038</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekstra FP, van Vught PW, van Rheenen W, et al. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33(3):630.e3-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.10.029</ArticleId></ArticleIdList></Reference><Reference><Citation>Theunissen F, Anderton RS, Mastaglia FL, et al. Novel STMN2 variant linked to amyotrophic lateral sclerosis risk and clinical phenotype. Front Aging Neurosci. 2021;13:658226&#x2013;658226.</Citation><ArticleIdList><ArticleId IdType="pubmed">33841129</ArticleId><ArticleId IdType="pmc">8033025</ArticleId><ArticleId IdType="doi">10.3389/fnagi.2021.658226</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR, Prudencio M, Koike Y, et al. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature. 2022;603(7899):124&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">35197626</ArticleId><ArticleId IdType="pmc">8891019</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04424-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22(2):167&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">30643292</ArticleId><ArticleId IdType="pmc">7153761</ArticleId><ArticleId IdType="doi">10.1038/s41593-018-0300-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AL, Wilkins OG, Keuss MJ, et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022;603(7899):131&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">35197628</ArticleId><ArticleId IdType="pmc">8891020</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04436-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardcastle N, Boulis NM, Federici T. AAV gene delivery to the spinal cord: serotypes, methods, candidate diseases, and clinical trials. Expert Opin Biol Ther. 2018;18(3):293&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">29249183</ArticleId><ArticleId IdType="doi">10.1080/14712598.2018.1416089</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C, Berry JD, McKenna-Yasek DM, et al. SOD1 suppression with adeno-associated virus and microRNA in familial ALS. N Engl J Med. 2020;383(2):151&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640133</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2005056</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel F, Gernoux G, Sun H, et al. Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci Transl Med. 2018;10:465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau6414</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica L, Todeasa SH, Cabrera GT, et al. Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann Neurol. 2016;79(4):687&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">26891182</ArticleId><ArticleId IdType="pmc">5374859</ArticleId><ArticleId IdType="doi">10.1002/ana.24618</ArticleId></ArticleIdList></Reference><Reference><Citation>Hester ME, Foust KD, Kaspar RW, et al. AAV as a gene transfer vector for the treatment of neurological disorders: novel treatment thoughts for ALS. Curr Gene Ther. 2009;9(5):428&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">19860657</ArticleId><ArticleId IdType="doi">10.2174/156652309789753383</ArticleId></ArticleIdList></Reference><Reference><Citation>Lentz TB, Gray SJ, Samulski RJ. Viral vectors for gene delivery to the central nervous system. Neurobiol Dis. 2012;48(2):179&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">22001604</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2011.09.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LJ, Lu YY, Muramatsu S, et al. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci. 2002;22(16):6920&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12177190</ArticleId><ArticleId IdType="pmc">6757879</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.22-16-06920.2002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaspar BK, Llado J, Sherkat N, et al. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 2003;301(5634):839&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">12907804</ArticleId><ArticleId IdType="doi">10.1126/science.1086137</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Kaspar BK, Kops GJ, et al. Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann Neurol. 2005;57(5):773&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15852369</ArticleId><ArticleId IdType="pmc">1351126</ArticleId><ArticleId IdType="doi">10.1002/ana.20453</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust KD, Salazar DL, Likhite S, et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther. 2013;21(12):2148&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">24008656</ArticleId><ArticleId IdType="pmc">3863799</ArticleId><ArticleId IdType="doi">10.1038/mt.2013.211</ArticleId></ArticleIdList></Reference><Reference><Citation>Yacila G, Sari Y. Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis. Curr Med Chem. 2014;21(31):3583&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">24934355</ArticleId><ArticleId IdType="pmc">4182116</ArticleId><ArticleId IdType="doi">10.2174/0929867321666140601162710</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulin-Bri&#xe8;re A, Rezaei E, Pozzi S. Antibody-based therapeutic interventions for amyotrophic lateral sclerosis: a systematic literature review. Front Neurosci. 2021;15: 790114.</Citation><ArticleIdList><ArticleId IdType="pubmed">34912191</ArticleId><ArticleId IdType="pmc">8667723</ArticleId><ArticleId IdType="doi">10.3389/fnins.2021.790114</ArticleId></ArticleIdList></Reference><Reference><Citation>ALZFORUM. Latozinemab. THERAPEUTICS [online] 2022 2022 April 14 [cited 2022 August 7]. Available from: https://www.alzforum.org/therapeutics/latozinemab .</Citation></Reference><Reference><Citation>Terryn J, Verfaillie CM, Van Damme P. Tweaking progranulin expression: therapeutic avenues and opportunities. Front Mol Neurosci. 2021;14: 713031.</Citation><ArticleIdList><ArticleId IdType="pubmed">34366786</ArticleId><ArticleId IdType="pmc">8343103</ArticleId><ArticleId IdType="doi">10.3389/fnmol.2021.713031</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Je G, Pacut P, et al. Gene therapy in amyotrophic lateral sclerosis. Cells. 2022;11(13):2066.</Citation><ArticleIdList><ArticleId IdType="pubmed">35805149</ArticleId><ArticleId IdType="pmc">9265980</ArticleId><ArticleId IdType="doi">10.3390/cells11132066</ArticleId></ArticleIdList></Reference><Reference><Citation>MedlinePlus. Pharmacogenetic tests. Pharmacogenetic Tests; 2021 [cited 2022 August 5]. Available from: https://medlineplus.gov/lab-tests/pharmacogenetic-tests/ .</Citation></Reference><Reference><Citation>Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">21639808</ArticleId><ArticleId IdType="pmc">3549296</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1103782</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">16236737</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa052306</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Bo R, Tiloca C, Pensato V, et al. Novel optineurin mutations in patients with familial and sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2011;82(11):1239&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">21613650</ArticleId><ArticleId IdType="doi">10.1136/jnnp.2011.242313</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y, Ofengeim D, Najafov A, et al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science. 2016;353(6299):603&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27493188</ArticleId><ArticleId IdType="pmc">5444917</ArticleId><ArticleId IdType="doi">10.1126/science.aaf6803</ArticleId></ArticleIdList></Reference><Reference><Citation>Mifflin L, Hu Z, Dufort C, et al. A RIPK1-regulated inflammatory microglial state in amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2021;118(13).</Citation></Reference><Reference><Citation>van Eijk RPA, Jones AR, Sproviero W, et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology. 2017;89(18):1915&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">28978660</ArticleId><ArticleId IdType="pmc">5664299</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000004606</ArticleId></ArticleIdList></Reference><Reference><Citation>Center H. Sean M. Healey &amp; AMG Center for ALS HEALEY ALS Platform Trial. HEALEY ALS Platform Trial [online] [cited 2022 August 5]. Available from: https://www.massgeneral.org/neurology/als/research/platform-trial .</Citation></Reference><Reference><Citation>Leeuwen LV. TRICALS enrols first participants in phase 3 MAGNET platform trial for ALS. TRICALS (the Treatment Research Initiative to Cure ALS), in collaboration with ALS&#x2026; [online] 2022 2022-03-15 [cited 2022 2022-08-05]. Available from: https://www.tricals.org/en/news/tricals-enrols-first-participants-in-phase-3-magnet-platform-trial-for-als .</Citation></Reference><Reference><Citation>MND-SMART. Motor neuron disease&#x2014;systematic multi-arm adaptive randomised trial. MND-SMART [online] 2022 [cited 2022 April 22]; Available from: https://www.mnd-smart.org/ .</Citation></Reference><Reference><Citation>TRICALS. ALS trial research. TRICALS [online] 2022 [cited 2022 April 22]. Available from: https://www.tricals.org/ .</Citation></Reference><Reference><Citation>NEALS. Northeast Amyotrophic Lateral Sclerosis Consortium. NEALS [online] 2022 [cited 2022 August 5]. Available from: https://www.neals.org/ .</Citation></Reference><Reference><Citation>PACTALS. Pan-Asian Consortium for Treatment and Research in ALS. PACTALS [online] 2022 [cited 2022 August 5]. Available from: https://pactals.org/ .</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>